Ultimovacs - INITIUM: March 2024 top-line timeline confirmed
Ultimovacs has confirmed that top-line results for the Phase II INITIUM trial (investigating lead candidate UV1 in combination with ipilimumab and nivolumab as first-line treatment for malignant melanoma, n=156) will be reported as planned in March 2024. This is a positive indicator that the trial is progressing, in our view, as the timeline had previously been pushed back twice (to H223 and H124) due to patients taking longer than expected to experience disease progression. Management has also confirmed that, while 70 progression events have not yet occurred, 18 months of follow-up for the last enrolled patient has been completed, thus enabling data analysis to commence. We view the latest announcement as an encouraging sign and believe that the upcoming INITIUM readout could be a significant catalyst for investor attention.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.